Minocycline Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:413871574
Tradename:Minocin, Amzeeq, others
Dailymedid:Minocycline
Pregnancy Au:D
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth, intravenous, topical
Class:Antibiotic
Tetracycline antibiotic
Atc Prefix:J01
Atc Suffix:AA08
Atc Supplemental:,
Legal Au:S4
Legal Us:Rx-only
Legal Us Comment:[2]
Bioavailability:90–100%
Protein Bound:70–75%[3]
Metabolism:Liver
Elimination Half-Life:15.5h (11–26h)[4]
Excretion:Mostly fecal, 10–15% renal
Cas Number:10118-90-8
Pubchem:54675783
Drugbank:DB01017
Chemspiderid:16735907
Unii:FYY3R43WGO
Kegg:D05045
Chebi:50694
Chembl:1434
Iupac Name:(2E,4S,4aR,5aS,12aR)-2-(Amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6- tetrahydro-4H-tetracene-1,3,12-trione[5]
C:23
H:27
N:3
O:7
Smiles:CN(C)c1ccc(c2c1C[C@H]3C[C@H]4[C@@H](C(=C(C(=O)[C@]4(C(=C3C2=O)O)O)C(=O)N)O)N(C)C)O
Stdinchi:1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
Stdinchikey:DYKFCLLONBREIL-KVUCHLLUSA-N
Solubility:Low
Specific Rotation:
25
[\alpha]
D
= −166°

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia. It is generally (but not always) less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.[6] It is taken by mouth or applied to the skin.[7] [8]

Common side effects include nausea, diarrhea, dizziness, allergic reactions, and kidney problems.[7] Serious side effects may include anaphylaxis, a lupus-like syndrome, and easy sunburning.[7] Use in the later part of pregnancy may harm the baby and safety during breastfeeding is unclear.[9] It works by decreasing a bacterium's ability to make protein thus stopping its growth.[7]

Minocycline was patented in 1961 and came into commercial use in 1971.[10] It is available as a generic medication.[6] [11] In 2022, it was the 269th most commonly prescribed medication in the United States, with more than 900,000 prescriptions.[12] [13]

Medical uses

Acne

Minocycline and doxycycline are frequently used for the treatment of acne vulgaris.[14] [15] Minocycline is specifically indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in people nine years of age and older.[16] Both minocycline and doxycycline have similar levels of effectiveness and common adverse effects for acne, although doxycycline may have a slightly lower risk of adverse side effects.[17] Both oral/systemic and more recently topical formulations of minocycline are available to treat acne.[18]

Historically, oral minocycline has been an effective treatment for acne vulgaris.[19] However, acne that is caused by antibiotic-resistant bacteria is a growing problem in many countries.[20] In Europe and North America, a number of people with acne no longer respond well to treatment with tetracycline family antibiotics because their acne symptoms are caused by bacteria (primarily Cutibacterium acnes) that are resistant to these antibiotics. In order to reduce resistance rates as well as increase the effectiveness of treatment, oral antibiotics should be generally combined with topical acne creams such as benzoyl peroxide or a retinoid (tretinoin, adapalene, etc.).[21] There have also been concerns about systemic minocycline having a variety of rare adverse effects in terms of its use to treat acne.

Oral minocycline is used to treat acne for up to 3 to 4months. Data beyond 3 to 4months are limited.

Other infections

Minocycline is also used for other skin infections such as methicillin-resistant Staphylococcus aureus.[22]

Although minocycline's broader spectrum of activity, compared with other members of the group, includes activity against Neisseria meningitidis,[23] its use for prophylaxis is no longer recommended because of side effects (dizziness and vertigo).

It may be used to treat certain strains of methicillin-resistant S. aureus infection and a disease caused by drug-resistant Acinetobacter spp.[24]

A list of uses includes:

Minocycline has been reported to be effective in the eradication of UTIs and prostatitis.[28] [29]

Other uses

Both minocycline and doxycycline have shown effectiveness in asthma due to immune-suppressing effects.[30] Minocycline and doxycycline have modest effectiveness in treating rheumatoid arthritis.[31] However, the 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis does not include minocycline.[32]

Recent research indicate that centrally infused minocycline attenuates brain microglial activation, neuroinflammation, and sympathetic activation during pulmonary hypertension.[33]

Available forms

Minocycline is available in the form of 50 and 100mg oral capsules, among a variety of other formulations.[34] The oral form of minocycline is usually taken twice daily, once every 12hours, although divided doses four times daily can also be employed. Extended-release oral forms are also available. A topical formulation is available as well.

Contraindications

The drug is contraindicated in people with known hypersensitivity to tetracycline antibiotics, as there is complete cross sensitivity in this group. It is also contraindicated in people with severe liver impairment and after the 16th week of pregnancy.

Side effects

See also: List of dental abnormalities associated with cutaneous conditions.

Minocycline may cause upset stomach, diarrhea, dizziness, unsteadiness, drowsiness, mouth sores, migraines, and vomiting. It increases sensitivity to sunlight, and may affect the quality of sleep and rarely causes sleep disorders.[35] It has also been linked to cases of lupus.[36] Prolonged use of minocycline can lead to blue-gray staining of skin, fingernails, and scar tissue. This staining is not permanent, but can take a very long time for the skin color to return to normal; however, a muddy brown skin color in sun-exposed areas is usually permanent.[37] Permanent blue discoloration of gums or teeth discoloration may also occur. Rare but serious side effects include fever, yellowing of the eyes or skin, stomach pain, sore throat, vision changes, and mental changes, including depersonalization.[38] [39]

Occasionally, minocycline therapy may result in autoimmune disorders such as drug-related lupus and autoimmune hepatitis, which usually occurs in men who also developed minocycline-induced lupus; however, women are more likely to develop minocycline-induced lupus. Significant or complete recovery occurs in most people who develop minocycline-induced autoimmune problems within a period of a few weeks to a year of cessation of minocycline therapy. Autoimmune problems emerge during chronic therapy, but can sometimes occur after only short courses of a couple of weeks of therapy.[40] [41] Drug reaction with eosinophilia and systemic symptoms syndrome can occur during the first few weeks of therapy with minocycline.[41]

Minocycline, but not other tetracyclines, can cause vestibular disturbances with dizziness, ataxia, vertigo, and tinnitus. These effects are thought to be related to minocycline's greater penetration into the central nervous system. Vestibular side effects are much more common in women than in men, occurring in 50 to 70% of women receiving minocycline. As a result of the frequency of this bothersome side effect, minocycline is rarely used in female patients.[42] Minocycline's vestibular side effects typically resolve after discontinuation of the drug.[43] [44] [45] [46]

Symptoms of an allergic reaction include rash, itching, swelling, severe dizziness, and trouble breathing. Minocycline has also been reported to very rarely cause idiopathic intracranial hypertension (pseudotumor cerebri),[47] a side effect also more common in female patients, potentially leading to permanent vision damage if not recognized early and treated.[48]

Contrary to most other tetracycline antibiotics (doxycycline excluded), minocycline may be used in those with kidney disease, but may aggravate systemic lupus erythematosus.[49] It may also trigger or unmask autoimmune hepatitis.[50]

Minocycline can cause the rare condition of secondary intracranial hypertension, which has initial symptoms of headache, visual disturbances, dizziness, vomiting, and confusion.[51] Brain swelling and rheumatoid arthritis are rare side effects of minocycline in some people.[52]

Minocycline, like most tetracyclines, becomes dangerous past its expiration date.[53] While most prescription drugs lose potency after their expiration dates, tetracyclines are known to become toxic over time. Expired tetracyclines can cause serious damage to the kidney due to the formation of a degradation product, anhydro-4-epitetracycline.[53] Minocycline's absorption is impaired if taken at the same time of day as calcium or iron supplements. Unlike some of the other tetracycline group antibiotics, it can be taken with calcium-rich foods such as milk, although this does reduce the absorption slightly.[54]

Minocycline, like other tetracyclines, is associated with esophageal irritation and ulceration if insufficient fluids are taken with the drug before sleep.[55]

A 2007 study suggested that minocycline harms amyotrophic lateral sclerosis (ALS) patients. Patients on minocycline declined more rapidly than those on placebo. The mechanism of this side effect is unknown, although a hypothesis is that the drug exacerbated an autoimmune component of the primary disease. The effect does not seem to be dose-dependent because the patients on high doses did not do worse than those on the low doses.[56]

Other possible rare side effects of minocycline include hyperpigmentation and hypersensitivity reactions, among others.[57] It has been associated with more rare and serious adverse effects than other tetracyclines.[58] Some of the rare adverse effects of minocycline may result in death. This has spurred interest in topical instead of systemic minocycline for treatment of acne.

Minocycine has shown thyroid toxicity in animals, including in rodents, mini pigs, dogs, and monkeys.

The use of minocycline to treat acne has been associated with skin and gut dysbiosis (see antibiotic misuse).[59]

Overdose

Symptoms of minocycline overdose may include dizziness, nausea, and vomiting. There is no specific antidote for overdose of minocycline and treatment should be symptom-based and supportive. The drug is not removed by hemodialysis or peritoneal dialysis.

Interactions

The combination of minocycline with dairy, antacids, calcium and magnesium supplements, iron products, laxatives containing magnesium, or bile acid sequestrants may decrease minocycline's effectiveness by forming chelates. Combining it with isotretinoin, acitretin or other retinoids can increase the risk for intracranial hypertension. Minocycline significantly reduces concentrations of the anti-HIV drug atazanavir in the body.[60]

Pharmacology

Pharmacodynamics

Antibiotic activity

Minocycline mediates its antibiotic activity by binding to the 30S ribosomal subunit of bacteria and thereby inhibiting protein synthesis.[61] [62] It is primarily bacteriostatic. The drug is a broad-spectrum antibiotic and shows activity against a wide range of both Gram-positive and Gram-negative bacteria.

Other activities

Minocycline shows a number of off-target activities in addition to its antibiotic activity.[63] These include inhibition of matrix metalloproteinases (MMPs), anti-inflammatory effects, antiapoptotic effects, antioxidant effects, and neuroprotective effects.

Some other reported activities of minocycline include:

Pharmacokinetics

Absorption

Minocycline is quickly and nearly completely absorbed from the upper part of the small intestine. Taking it together with food, including milk, has no relevant influence on resorption. It reaches highest blood plasma concentrations after 1 to 2hours.

Distribution

The drug has a plasma protein binding of 70 to 75%. It penetrates into almost all tissues; very high concentrations are found in the gallbladder and liver. It crosses the blood–brain barrier better than doxycycline and other tetracyclines, reaching therapeutically relevant concentrations in the cerebrospinal fluid and also in inflamed meninges.[68] Minocycline achieves good concentrations in the urinary bladder, and many other tissues. It shows excellent penetration into the prostate gland.[69] However, while permeation of prostate tissue and semen is good, levels are lower in prosatic fluid.

Metabolism

Minocycline is inactivated by metabolism in the liver to about 50%. It is primarily metabolized into 9-hydroxyminocycline.[70] Two N-demethylated metabolites are also formed.

Elimination

The rest is predominantly excreted into the gut (in part via the gallbladder, in part directly from blood vessels) and eliminated via the feces. About 10–15% are eliminated via the kidneys. It is excreted about 5 to 10% unchanged in urine. For comparison, other tetracyclines, like doxycycline and tetracycline, are excreted 30 to 70% unchanged in urine. The biological half-life of minocycline is 11 to 26hours in healthy people, up to 30hours in those with kidney failure, and significantly longer in those with liver disease.

Chemistry

Minocycline is a tetracycline derivative.[71] It is closely structurally related to other tetracyclic antibiotics such as tetracycline, doxycycline, and tigecycline.

The drug is used in form of minocycline hydrochloride dihydrate, which is sparingly soluble in water and slightly soluble in ethanol. Minocycline reacts acidic in aqueous solution.

The partition coefficient (P) of minocycline has been reported to be 39.4 (i.e., log P of 1.60).[72] However, other sources have stated the experimental log P of minocycline to be 0.05,[73] 0.5,[74] and 1.1.[75] In any case, minocycline is consistently described as a highly lipophilic compound with excellent tissue penetration and distribution.[76] [77] It has been said to be unique among the tetracyclines in that it is the most lipophilic of all of the members of this group. Minocycline has 10 to 30times greater lipophilicity than tetracycline and 5times greater lipophilicity than doxycycline. The improved lipophilicity of minocycline is thought to be advantageous in terms of its clinical antibiotic effectiveness.

History

Minocycline was patented in 1961, was first described in the scientific literature in 1967, and came into commercial use in 1971. A topical foam for treatment of acne was approved in 2019.

Society and culture

Brand names

Generic availability

It is available as a generic medication.[6]

Research

Neuropsychiatric disorders

Minocycline has been studied for treatment-resistant depression. According to a 2023 systematic review based on four clinical trials, "There is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy."[79]

Early research has found a tentative benefit from minocycline in schizophrenia,[80] with several trials underway.[81] A 2014 meta-analysis found minocycline may reduce negative and total symptom scores and was well tolerated.[82]

Some early studies suggest that minocycline may be beneficial as an add-on treatment for moderate-to-severe obsessive-compulsive disorder (OCD) when used with an SSRI.[83] [84]

Stroke and neurodegenerative diseases

In ongoing research and trial, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup. Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients.[85]

Research is examining the possible neuroprotective and anti-inflammatory effects of minocycline against the progression of a group of neurodegenerative disorders including multiple sclerosis, rheumatoid arthritis, Huntington's disease, and Parkinson's disease.[86] [87] [88] [89] As mentioned above, minocycline harms ALS patients.

A trial found no difference between minocycline and placebo in people with Alzheimers' disease.[90] Minocycline is somewhat neuroprotective in mouse models of Huntington's disease.[91]

Multiple sclerosis

A 2007 study reported the impact of the antibiotic minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in 40 MS patients over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment relapse rate in the patient group prior to treatment (1.3/year pre-enrollment; 1.2/year during a three-month baseline period), no relapses occurred between months 6 and 24 on minocycline. Also, despite significant MRI disease-activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Levels of interleukin-12 (IL-12), which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascular cell adhesion molecule-1 (VCAM-1). The activity of matrix metalloproteinase-9 was decreased by treatment. Clinical and MRI outcomes in this study were supported by systemic immunological changes and call for further investigation of minocycline in MS.[92] [93] [94]

Hearing protection

Several preclinical studies (in vitro cell cultures and animal models) suggest that minocycline may have otoprotective benefits. Animal models indicate it could potentially reduce noise-induced and blast-induced hearing loss, possibly by protecting hair cells and mitigating inflammation.[95] [96] In vitro and animal studies also show minocycline may help decrease ototoxicity from certain drugs like gentamicin,[97] neomycin,[98] and cisplatin.[99] [100]

Other uses

Minocycline also has been used as a "last-ditch" treatment for toxoplasmosis in AIDS patients.[101]

Notes and References

  1. Web site: Minocycline Use During Pregnancy . Drugs.com . 4 December 2018 . 16 May 2020.
  2. Web site: Minocin- minocycline hydrochloride injection . DailyMed . 28 July 2021 . 19 February 2023.
  3. Book: Arzneistoff-Profile. Dinnendahl V, Fricke U . Govi Pharmazeutischer Verlag. Eschborn, Germany. 2010. 24. 7. Minocyclin . 978-3-7741-9846-3 . de.
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050649s028lbl.pdf
  5. Web site: Minocycline. go.drugbank.com.
  6. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 556. 76.
  7. Web site: Minocycline Hydrochloride Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 23 March 2019 .
  8. Web site: Amzeeq- minocycline aerosol, foam . DailyMed . 25 January 2023 . 18 February 2023.
  9. Web site: Minocycline Use During Pregnancy . Drugs.com . 3 March 2019 . en.
  10. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery. 2006. John Wiley & Sons. 9783527607495. 489. en.
  11. Web site: First Generic Drug Approvals . U.S. Food and Drug Administration . 17 October 2022 . 28 November 2022.
  12. Web site: The Top 300 of 2022 . ClinCalc . 30 August 2024 . 30 August 2024 . https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  13. Web site: Minocycline Drug Usage Statistics, United States, 2013 - 2022 . ClinCalc . 30 August 2024 .
  14. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R . Guidelines of care for acne vulgaris management . Journal of the American Academy of Dermatology . 56 . 4 . 651–663 . April 2007 . 17276540 . 10.1016/j.jaad.2006.08.048 .
  15. Web site: Minocycline, Doxycycline and Acne Vulgaris . ScienceOfAcne.com . 7 August 2012. https://web.archive.org/web/20120807133359/http://scienceofacne.com:80/doxycycline-and-minocycline. 7 August 2012.
  16. Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, Freeman EE, Keri JE, Stein Gold LF, Tan JK, Tollefson MM, Weiss JS, Wu PA, Zaenglein AL, Han JM, Barbieri JS . Guidelines of care for the management of acne vulgaris . J Am Acad Dermatol . 90 . 5 . 1006.e1–1006.e30 . May 2024 . 38300170 . 10.1016/j.jaad.2023.12.017 .
  17. Kircik LH . Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications . Journal of Drugs in Dermatology . 9 . 11 . 1407–1411 . November 2010 . 21061764 .
  18. Onge ES, Mobley WC . Minocycline Topical Foam: A New Drug for the Treatment of Acne . Ann Pharmacother . 55 . 1 . 105–110 . January 2021 . 32618475 . 10.1177/1060028020939926 .
  19. Hubbell CG, Hobbs ER, Rist T, White JW . Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris . Archives of Dermatology . 118 . 12 . 989–992 . December 1982 . 6216858 . 10.1001/archderm.1982.01650240033017 .
  20. Eady EA, Gloor M, Leyden JJ . Propionibacterium acnes resistance: a worldwide problem . Dermatology . 206 . 1 . 54–56 . 2003 . 12566805 . 10.1159/000067822 . 6111436 .
  21. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Peréz Del Pulgar JI, Rollman O, Török L, Eady EA, Cove JH . Antibiotic-resistant acne: lessons from Europe . The British Journal of Dermatology . 148 . 3 . 467–478 . March 2003 . 12653738 . 10.1046/j.1365-2133.2003.05067.x . 0706.4406 . 20838517 . 10454/3069 .
  22. Rogers RL, Perkins J . Skin and soft tissue infections . Primary Care . 33 . 3 . 697–710 . September 2006 . 17088156 . 10.1016/j.pop.2006.06.005 .
  23. Fraser A, Gafter-Gvili A, Paul M, Leibovici L . Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials . European Journal of Clinical Microbiology & Infectious Diseases . 24 . 3 . 172–181 . March 2005 . 15782277 . 10.1007/s10096-005-1297-7 . 1259483 .
  24. Bishburg E, Bishburg K . Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii . International Journal of Antimicrobial Agents . 34 . 5 . 395–401 . November 2009 . 19665876 . 10.1016/j.ijantimicag.2009.06.021 .
  25. Copeland KF, Brooks JI . A novel use for an old drug: the potential for minocycline as anti-HIV adjuvant therapy . The Journal of Infectious Diseases . 201 . 8 . 1115–1117 . April 2010 . 20205572 . 10.1086/651278 . free .
  26. Mungroo MR, Khan NA, Siddiqui R . Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options . Microbial Pathogenesis . 149 . 104475 . December 2020 . 32931893 . 10.1016/j.micpath.2020.104475 . 221748544 .
  27. U.S. National Library of Medicine (11 December 2009) 'Perioral dermatitis'. Retrieved 7 August 2010.
  28. Perletti G, Marras E, Wagenlehner FM, Magri V . Antimicrobial therapy for chronic bacterial prostatitis . Cochrane Database Syst Rev . 2013 . 8 . CD009071 . August 2013 . 23934982 . 11361477 . 10.1002/14651858.CD009071.pub2 .
  29. Hanus PM, Danziger LH . Treatment of chronic bacterial prostatitis . Clin Pharm . 3 . 1 . 49–55 . 1984 . 6365416 .
  30. Joks R, Durkin HG . Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs . Pharmacological Research . 64 . 6 . 602–609 . December 2011 . 21501686 . 10.1016/j.phrs.2011.04.001 .
  31. Greenwald RA . The road forward: the scientific basis for tetracycline treatment of arthritic disorders . Pharmacological Research . 64 . 6 . 610–613 . December 2011 . 21723947 . 10.1016/j.phrs.2011.06.010 .
  32. Web site: Clinical Practice Guidelines: Rheumatoid Arthritis. American College of Rheumatology. 13 May 2017.
  33. Sharma RK, Oliveira AC, Kim S, Rigatto K, Zubcevic J, Rathinasabapathy A, Kumar A, Lebowitz JJ, Khoshbouei H, Lobaton G, Aquino V, Richards EM, Katovich MJ, Shenoy V, Raizada MK . Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension . Hypertension . 71 . 6 . 1156–1163 . June 2018 . 29712738 . 5945302 . 10.1161/HYPERTENSIONAHA.118.10934 .
  34. Web site: Drugs@FDA: FDA-Approved Drugs . accessdata.fda.gov . 2 December 2024.
  35. Nonaka K, Nakazawa Y, Kotorii T . Effects of antibiotics, minocycline and ampicillin, on human sleep . Brain Research . 288 . 1–2 . 253–259 . December 1983 . 6661620 . 10.1016/0006-8993(83)90101-4 . 22726747 .
  36. News: MedlinePlus Drug Information: Minocycline Oral .
  37. Geria AN, Tajirian AL, Kihiczak G, Schwartz RA . Minocycline-induced skin pigmentation: an update . Acta Dermatovenerologica Croatica . 17 . 2 . 123–126 . 2009 . 19595269 .
  38. Web site: minocycline (Dynacin): Antibiotic Side Effects & Dosage. MedicineNet.
  39. Cohen PR . Medication-associated depersonalization symptoms: report of transient depersonalization symptoms induced by minocycline . Southern Medical Journal . 97 . 1 . 70–73 . January 2004 . 14746427 . 10.1097/01.SMJ.0000083857.98870.98 . 27125601 .
  40. Mongey AB, Hess EV . Drug insight: autoimmune effects of medications-what's new? . Nature Clinical Practice. Rheumatology . 4 . 3 . 136–144 . March 2008 . 18200008 . 10.1038/ncprheum0708 . 205340777 .
  41. Ochsendorf F . Minocycline in acne vulgaris: benefits and risks . American Journal of Clinical Dermatology . 11 . 5 . 327–341 . 2010 . 20642295 . 10.2165/11319280-000000000-00000 . 24501240 .
  42. Book: Sweet RL, Gibbs RS . Infectious Diseases of the Female Genital Tract . 4th . 2001 . Lippincott Williams & Wilkins . 635.
  43. Book: Bauman N . Ototoxic Drugs Exposed . 2010 . 978-1-935939-00-9 . 3 . 435–436 . Integrity First Publications . You can develop symptoms of ototoxicity after only one or two doses. These symptoms normally disappear a day or two after you stop taking this drug..
  44. Web site: Minocycline Side Effects: Common, Severe, Long Term . Drugs.com . 27 December 2023 . 16 January 2024 . https://web.archive.org/web/20240116091026/https://www.drugs.com/sfx/minocycline-side-effects.html . 16 January 2024 . Headache, dizziness, vertigo, and ataxia have been reported. These side effects were reversible within 3 to 48 hours of stopping therapy and occurred less often with low doses..
  45. Williams DN, Laughlin LW, Lee YH . Minocycline: Possible vestibular side-effects . Lancet . 2 . 7883 . 744–6 . September 1974 . 4143012 . 10.1016/s0140-6736(74)90941-6 . 17 (89%) of 19 persons taking minocycline for the treatment of bacteriuria or for prophylaxis of meningococcal disease developed nausea, vomiting, weakness, ataxia, vertigo, or dizziness, 24-48 hours after the initiation of therapy. These symptoms usually occurred in combination, were often acute and severe, and disappeared shortly after therapy was discontinued..
  46. Jacobson JA, Daniel B . Vestibular reactions associated with minocycline . Antimicrobial Agents and Chemotherapy . 8 . 4 . 453–6 . October 1975 . 1081373 . 429369 . 10.1128/AAC.8.4.453.
  47. Friedman DI . Medication-induced intracranial hypertension in dermatology . American Journal of Clinical Dermatology . 6 . 1 . 29–37 . 2005 . 15675888 . 10.2165/00128071-200506010-00004 . 28395784 .
  48. Mechrgui M, Kanani S . The Ophthalmic Side Effects of Topiramate: A Review . Cureus . 14 . 8 . e28513 . August 2022 . 36059357 . 9420653 . 10.7759/cureus.28513 . free .
  49. Gough A, Chapman S, Wagstaff K, Emery P, Elias E . Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome . BMJ . 312 . 7024 . 169–172 . January 1996 . 8563540 . 2349841 . 10.1136/bmj.312.7024.169 .
  50. Krawitt EL . Autoimmune hepatitis . The New England Journal of Medicine . 354 . 1 . 54–66 . January 2006 . 16394302 . 10.1056/NEJMra050408 . 5361674 .
  51. Friedman DI . Medication-induced intracranial hypertension in dermatology . American Journal of Clinical Dermatology . 6 . 1 . 29–37 . 2005 . 15675888 . 10.2165/00128071-200506010-00004 . Springer Science and Business Media LLC . 28395784 .
  52. Lefebvre N, Forestier E, Farhi D, Mahsa MZ, Remy V, Lesens O, Christmann D, Hansmann Y . Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report . Journal of Medical Case Reports . 1 . 22 . May 2007 . 17511865 . 1884162 . 10.1186/1752-1947-1-22 . free .
  53. "Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals". Environmental health criteria: 119. World Health Organization (WHO). . ISSN 0250-863X. 1991
  54. Book: Drug Interactions in Infectious Diseases . Piscitelli SC, Rodvold K . 2005 . Humana Press . 978-1-58829-455-5 . registration .
  55. Drugs.com 'Minocycline Disease Interactions'. Retrieved 12 February 2017.
  56. Couzin J . Clinical research. ALS trial raises questions about promising drug . Science . 318 . 5854 . 1227 . November 2007 . 18033854 . 10.1126/science.318.5854.1227a . 72187805 .
  57. Dominic MR . Adverse Reactions Induced by Minocycline: A Review of Literature . Curr Drug Saf . 16 . 3 . 309–321 . 2021 . 33494681 . 10.2174/1574886316666210120090446 .
  58. Martins AM, Marto JM, Johnson JL, Graber EM . A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea . Antibiotics (Basel) . 10 . 7 . June 2021 . 757 . 34206485 . 8300648 . 10.3390/antibiotics10070757 . free .
  59. Thompson KG, Rainer BM, Antonescu C, Florea L, Mongodin EF, Kang S, Chien AL . Minocycline and Its Impact on Microbial Dysbiosis in the Skin and Gastrointestinal Tract of Acne Patients . Annals of Dermatology . 32 . 1 . 21–30 . February 2020 . 33911705 . 7992645 . 10.5021/ad.2020.32.1.21 . free .
  60. Web site: Minocycline. mediQ. 6 August 2020.
  61. Asadi A, Abdi M, Kouhsari E, Panahi P, Sholeh M, Sadeghifard N, Amiriani T, Ahmadi A, Maleki A, Gholami M . Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future . J Glob Antimicrob Resist . 22 . 161–174 . September 2020 . 32061815 . 10.1016/j.jgar.2020.01.022 .
  62. Garrido-Mesa N, Zarzuelo A, Gálvez J . What is behind the non-antibiotic properties of minocycline? . Pharmacol Res . 67 . 1 . 18–30 . January 2013 . 23085382 . 10.1016/j.phrs.2012.10.006 .
  63. Singh S, Khanna D, Kalra S . Minocycline and Doxycycline: More Than Antibiotics . Curr Mol Pharmacol . 14 . 6 . 1046–1065 . 2021 . 33568043 . 10.2174/1874467214666210210122628 .
  64. Alano CC, Kauppinen TM, Valls AV, Swanson RA . Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations . Proceedings of the National Academy of Sciences of the United States of America . 103 . 25 . 9685–9690 . June 2006 . 16769901 . 1480467 . 10.1073/pnas.0600554103 . free . 2006PNAS..103.9685A .
  65. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J . Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia . The Journal of Neuroscience . 21 . 8 . 2580–2588 . April 2001 . 11306611 . 6762519 . 10.1523/JNEUROSCI.21-08-02580.2001 .
  66. Web site: minomycin-if . 8 September 2017 . 8 September 2017 . https://web.archive.org/web/20170908112018/http://www.info.pmda.go.jp/go/interview/2/671450_6152005F1052_2_1F.pdf . dead .
  67. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB . A novel mechanism of action of tetracyclines: effects on nitric oxide synthases . Proceedings of the National Academy of Sciences of the United States of America . 93 . 24 . 14014–14019 . November 1996 . 8943052 . 19486 . 10.1073/pnas.93.24.14014 . free . 1996PNAS...9314014A .
  68. Book: Austria-Codex. Haberfeld H . Minostad 50 mg-Kapseln. Österreichischer Apothekerverlag. Vienna. 2020. de.
  69. Cunha BA, Garabedian-Ruffalo SM . Tetracyclines in urology: current concepts . Urology . 36 . 6 . 548–556 . December 1990 . 2247929 . 10.1016/0090-4295(90)80201-w .
  70. Web site: Minocycline: Uses, Interactions, Mechanism of Action . DrugBank Online . 30 June 1971 . 2 December 2024.
  71. Bahrami F, Morris DL, Pourgholami MH . Tetracyclines: drugs with huge therapeutic potential . Mini Rev Med Chem . 12 . 1 . 44–52 . January 2012 . 22070692 . 10.2174/138955712798868977 .
  72. Saivin S, Houin G . Clinical pharmacokinetics of doxycycline and minocycline . Clin Pharmacokinet . 15 . 6 . 355–366 . December 1988 . 3072140 . 10.2165/00003088-198815060-00001 .
  73. Web site: Minocycline: Uses, Interactions, Mechanism of Action . DrugBank Online . 30 June 1971 . 2 December 2024.
  74. Fuoco D . Classification Framework and Chemical Biology of Tetracycline-Structure-Based Drugs . Antibiotics (Basel) . 1 . 1 . 1–13 . June 2012 . 27029415 . 4790241 . 10.3390/antibiotics1010001 . free .
  75. Book: Florence AT, Attwood D . Physicochemical Principles of Pharmacy . Solubility and Partitioning of Drugs . Macmillan Education UK . London . 1988 . 978-0-333-23405-1 . 10.1007/978-1-349-16558-2_5 . 131–171.
  76. Leyden JJ, Del Rosso JQ . Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives . J Clin Aesthet Dermatol . 4 . 2 . 40–47 . February 2011 . 21386956 . 3050614 .
  77. Jonas M, Cunha BA . Minocycline . Ther Drug Monit . 4 . 2 . 137–145 . 1982 . 7048646 . 10.1097/00007691-198206000-00002 .
  78. Web site: How ARESTIN is supplied and dosed. OraPharma, Inc.. 1 January 2010. 9 January 2010. https://web.archive.org/web/20100109103746/http://www.arestin.com/for-professionals-easy-administer.jsp. dead.
  79. Shamim MA, Manna S, Dwivedi P, Swami MK, Sahoo S, Shukla R, Srivastav S, Thaper K, Saravanan A, Anil A, Varthya SB, Singh S, Shamim MA, Satapathy P, Chattu SK, Chattu VK, Padhi BK, Sah R . Minocycline in depression not responding to first-line therapy: A systematic review and meta-analysis . Medicine . 102 . 45 . e35937 . November 2023 . 37960804 . 10.1097/MD.0000000000035937 . free . 10637431 .
  80. Dean OM, Data-Franco J, Giorlando F, Berk M . Minocycline: therapeutic potential in psychiatry . CNS Drugs . 26 . 5 . 391–401 . May 2012 . 22486246 . 10.2165/11632000-000000000-00000 .
  81. Will Antibiotic Fulfill Its Psychosis-Fighting Promise?. Psychiatric News. 47. 16. 10. Arehart-Treichel J . 17 August 2012. 10.1176/pn.47.16.psychnews_47_16_10-a.
  82. Oya K, Kishi T, Iwata N . Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials . Human Psychopharmacology . 29 . 5 . 483–491 . September 2014 . 25087702 . 10.1002/hup.2426 . 3564390 .
  83. van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI . Treatment-resistant OCD: Pharmacotherapies in adults . Comprehensive Psychiatry . 120 . 152352 . January 2023 . 36368186 . 10.1016/j.comppsych.2022.152352. 2445/192315 . free .
  84. Panizzutti B, Skvarc D, Lin S, Croce S, Meehan A, Bortolasci CC, Marx W, Walker AJ, Hasebe K, Kavanagh BE, Morris MJ, Mohebbi M, Turner A, Gray L, Berk L, Walder K, Berk M, Dean OM . Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis . International Journal of Molecular Sciences . 24 . 6 . March 2023 . 5250 . 36982324 . 10049047 . 10.3390/ijms24065250. free .
  85. Malhotra K, Chang JJ, Khunger A, Blacker D, Switzer JA, Goyal N, Hernandez AV, Pasupuleti V, Alexandrov AV, Tsivgoulis G . Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials . Journal of Neurology . 265 . 8 . 1871–1879 . August 2018 . 29948247 . 10.1007/s00415-018-8935-3 . free . 49431206 . 10757/624615 .
  86. Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson's Disease . National Institute of Health . 23 February 2006 .
  87. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM . Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease . Nature Medicine . 6 . 7 . 797–801 . July 2000 . 10888929 . 10.1038/77528 . 22681391 .
  88. Tikka TM, Koistinaho JE . Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia . Journal of Immunology . 166 . 12 . 7527–7533 . June 2001 . 11390507 . 10.4049/jimmunol.166.12.7527 . free .
  89. Nirmalananthan N, Greensmith L . Amyotrophic lateral sclerosis: recent advances and future therapies . Current Opinion in Neurology . 18 . 6 . 712–719 . December 2005 . 16280684 . 10.1097/01.wco.0000187248.21103.c5 . 3255995 .
  90. Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R . Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial . JAMA Neurology . 77 . 2 . 164–174 . February 2020 . 31738372 . 6865324 . 10.1001/jamaneurol.2019.3762 . free .
  91. Beal MF, Ferrante RJ . Experimental therapeutics in transgenic mouse models of Huntington's disease . Nature Reviews. Neuroscience . 5 . 5 . 373–384 . May 2004 . 15100720 . 10.1038/nrn1386 . 19496441 .
  92. Zemke D, Majid A . The potential of minocycline for neuroprotection in human neurologic disease . Clinical Neuropharmacology . 27 . 6 . 293–298 . 2004 . 15613934 . 10.1097/01.wnf.0000150867.98887.3e . 30431947 .
  93. Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, Williams SK, Neusch C, Bähr M, Diem R . Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation . Neurobiology of Disease . 25 . 3 . 514–525 . March 2007 . 17239606 . 10.1016/j.nbd.2006.10.022 . 39628457 .
  94. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID . Inhibition of autoimmune encephalomyelitis by a tetracycline . Annals of Neurology . 51 . 2 . 215–223 . February 2002 . 11835378 . 10.1002/ana.10092 . 21209994 .
  95. Zhang J, Song YL, Tian KY, Qiu JH . Minocycline attenuates noise-induced hearing loss in rats . Neuroscience Letters . 639 . 31–35 . February 2017 . 28007648 . 10.1016/j.neulet.2016.12.039. 38379616 .
  96. Perumal V, Ravula AR, Shao N, Chandra N . Effect of minocycline and its nano-formulation on central auditory system in blast-induced hearing loss rat model . Journal of Otology . 18 . 1 . 38–48 . January 2023 . 36820161 . 9937842 . 10.1016/j.joto.2022.09.002.
  97. Wei X, Zhao L, Liu J, Dodel RC, Farlow MR, Du Y . Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation . . 131 . 2 . 513–21 . 2005 . 15708492 . 10.1016/j.neuroscience.2004.11.014. 3125930 .
  98. Robinson AM, Vujanovic I, Richter CP . Minocycline protection of neomycin induced hearing loss in gerbils . BioMed Research International . 2015 . 934158 . 2015 . 25950003 . 4407513 . 10.1155/2015/934158. free .
  99. Lee CK, Shin JI, Cho YS . Protective Effect of Minocycline Against Cisplatin-induced Ototoxicity . Clinical and Experimental Otorhinolaryngology . 4 . 2 . 77–82 . June 2011 . 21716954 . 3109331 . 10.3342/ceo.2011.4.2.77.
  100. Du B, Zhang Y, Tang Y, Wang P . Minocycline attenuates ototoxicity and enhances antitumor activity of cisplatin treatment in vitro . Otolaryngology–Head and Neck Surgery . 144 . 5 . 719–25 . May 2011 . 21493367 . 10.1177/0194599810395090. 25994657 .
  101. Lacassin F, Schaffo D, Perronne C, Longuet P, Leport C, Vilde JL . Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus . Antimicrobial Agents and Chemotherapy . 39 . 1 . 276–277 . January 1995 . 7695324 . 162527 . 10.1128/AAC.39.1.276 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Minocycline".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.